Treating Schizophrenia With the Diuretic Bumetanide: A Case ReportLemonnier, Eric MD; Lazartigues, Alain MD, PhD; Ben-Ari, Yehezkel PhDClinical Neuropharmacology: March/April 2016 - Volume 39 - Issue 2 - p 115–117 doi: 10.1097/WNF.0000000000000136 Case Reports Buy Abstract Author InformationAuthors Article MetricsMetrics Administration of the diuretic and NKCC1 chloride cotransporter antagonist bumetanide reduces the severity of autism spectrum disorders in children, and this effect is mediated by a reduction of the elevated intracellular chloride concentrations and a reinforcement of GABAergic inhibition (Lemonnier et al Transl Psychiatry. 2012;2:e202; Tyzio et al Science. 2014;343:675–679). Here, we report that this treatment also reduces the severity of symptoms in an adolescent with schizophrenia. Long-term treatment reduced hallucinations significantly, suggesting that this treatment may also be useful to treat schizophrenia. Further clinical trials and experimental studies are warranted to test this hypothesis. *Centre Expert Autisme Limousin, Limoges; and †Neurochlore c/o Inmed, INSERM U901, Marseilles, France. Address correspondence and reprint requests to Eric Lemonnier, MD, Centre Expert Autisme Limousin, CHU Limoges, Hopital Le Cluzeau, 23 Avenue Dominique Larrey, 87000 Limoges, France; E-mail: email@example.com; Yehezkel Ben-Ari, PhD, Neurochlore c/o Inmed, INSERM U901, 163 Route de Luminy, Marseilles 13273, France; E-mail: firstname.lastname@example.org Conflicts of Interest and Source of Funding: E.L and Y.B.-A. are founders of Neurochlore a company devoted to develop novel treatments for autism. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.